ODYSSEY LEGACY; Long-Term effects of LDL-C lowering with Alirocumab.
Research type
Research Study
Full title
Long-term legacy effects of LDL-C lowering with alirocumab: observational follow-up of the ODYSSEY OUTCOMES study.
IRAS ID
235797
Contact name
Kausik Ray
Contact email
Sponsor organisation
Sanofi
Duration of Study in the UK
11 years, 0 months, 1 days
Research summary
This is an observational study designed to determine the long-term effects of alirocumab taken by subjects who participated in the parent Odyssey outcomes study. Patients completing the Odyssey outcomes study will be invited to participate in this study which is looking at CV mortality through an extended observational period of up to 10 years. This study plans to collect information on hospitalization for major CV events, deaths (CV-related and non-CV related), and use of Lipid Lowering Treatments. The data will be collected yearly from patients, their designated contacts, or their healthcare provider via electronic patient reported outcome (ePRO), phone, fax, mail or text.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
17/NW/0656
Date of REC Opinion
12 Dec 2017
REC opinion
Further Information Favourable Opinion